Resumption of public service and special arrangement of Consumer Advice Centres
The Consumer Council Services Centre located at Tsim Sha Tsui and North Point Consumer Advice Centre will resume normal service from 18 May 2020 (Monday).
To reduce the risk of the spread of COVID-19, social distancing and other precautionary measures will be implemented at Consumer Advice Centres.
Visitors are required to:
- Make prior appointment for service by calling the hotline 2929 2222;
- Wear surgical face masks and take a body temperature check before entering the Centres;
- Wait in a designated waiting area in order to reduce social contacts with other visitors.
(Notes: Visitors may experience a longer waiting time because of the precautionary measures.)
Batch recall of Syntometrine Injection (with photo)
The Department of Health (DH) today (April 3) endorsed a licensed drug wholesaler, Healthcare Division O/B DCH Auriga (Hong Kong) Limited (Auriga), to recall one batch (batch number: 60748) of Syntometrine Injection (Hong Kong Registration number: HK-01698) from the market because of a potential quality issue.
The DH received notification from Auriga that the manufacturer of the product in Germany reported that, during handling a complaint of content discoloration, the results revealed the content of the active ingredients and degradation products of the batch were out of specification, which might affect the efficacy of the product. According to the preliminary investigation by the manufacturer, other batches are not affected by the issue.
Auriga voluntarily recalled the batch of the product from the market and was instructed to report the root cause to the DH upon investigation by the manufacturer in Germany.
The above product, containing Ergometrine and Oxytocin, is a prescription medicine used for active management of the third stage of labour and treatment of post-partum haemorrhage. According to Auriga, the affected batch of product has been supplied to the Hospital Authority, private hospitals and a private doctor.
Auriga has set up a hotline (2635 5986) to answer related enquiries.
"So far, the DH has not received any adverse reaction report in connection with the affected batch of the product. The DH will continue its investigation and will closely monitor the recall," a spokesman for the DH said.
Reposted from HKSAR Government webpage: